Nomura has a buy on Dr Reddy’s Labs, target price Rs 3,200

Nomura has a buy rating on Dr Reddy’s Laboratories in the long term with a target price of Rs 3,200. Shares of Dr Reddy’s Laboratories ended down 0.2% at Rs 2,816.25 on Monday while BSE Sensex closed 70.99 points down at 40,938.72.

Company Financials

For the quarter ended 30-09-2019, the company has reported consolidated sales of Rs 4800.80 crore, up 24.90% from last quarter sales of Rs 3843.60 crore and up 30.22 % from last year same quarter sales of Rs 3686.60 crore. The company has reported net profit after tax of Rs 1095.10 crore in the latest quarter.


The company’s top management includes Dr.Bruce L A Carter, Mr.Allan Oberman, Mr.Bharat N Doshi, Mr.G V Prasad, Mr.K Satish Reddy, Mr.Leo Puri, Mr.Prasad R Menon, Mr.Sridar Iyengar, Ms.Kalpana Morparia, Ms.Shikha Sharma. Company has S R Batliboi & Associates LLP as its auditors. As on 30-09-2019, the company has a total of 166,145,748 shares outstanding.

Investment Rationale

Amneal is the first generic company to receive approval for a generic version of Nuvaring, said Nomura. Dr Reddy’s and Teva are the other known filers, it said. Amneal will have first-mover advantage; hence, the upside for Dr Reddy’s is likely to be curtailed to an extent, it said.